Evidence map›Paper›PMID 37774943›Full record

ArticleNeuropharmacology2023

Decreased myelin-related gene expression in the nucleus accumbens during spontaneous neonatal opioid withdrawal in the absence of long-term behavioral effects in adult outbred CFW mice.

Kristyn N Borrelli, Kelly K Wingfield, Emily J Yao, Catalina A Zamorano, Katherine D Sena, Jacob A Beierle, Michelle A Roos, Huiping Zhang, Elisha M Wachman, Camron D Bryant

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Epigenetic mechanisms of HIV and opioid-induced neuropathology: Potential therapies and interventions.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Kristyn N BorrelliGraduate Program for Neuroscience, Boston University, 610 Commonwealth Av, Boston, MA, 02215, USA; T32 Biomolecular Pharmacology PhD Program, Boston University Chobanian & Avedisian School of Medicine, USA; Boston University's Transformative Training Program in Addiction Science, Boston University Chobanian & Avedisian School of Medicine, 72 E. Concord St., L-317, Boston, MA, 02118, USA.
Kelly K WingfieldT32 Biomolecular Pharmacology PhD Program, Boston University Chobanian & Avedisian School of Medicine, USA; Laboratory of Addiction Genetics, Department of Pharmacology, Physiology & Biophysics, Boston University Chobanian & Avedisian School of Medicine, 72 E. Concord St., L-606, Boston, MA, 02118, USA; Department of Pharmaceutical Sciences, Center for Drug Discovery, Northeastern University, 360 Huntington Av, 140 The Fenway Building, X138, Boston, MA, 02115, USA.
Emily J YaoLaboratory of Addiction Genetics, Department of Pharmacology, Physiology & Biophysics, Boston University Chobanian & Avedisian School of Medicine, 72 E. Concord St., L-606, Boston, MA, 02118, USA; Department of Pharmaceutical Sciences, Center for Drug Discovery, Northeastern University, 360 Huntington Av, 140 The Fenway Building, X138, Boston, MA, 02115, USA.
Catalina A ZamoranoBoston University's Undergraduate Research Opportunity Program, George Sherman Union, 775 Commonwealth Av, 5th floor, Boston, MA, 02215, USA.
Katherine D SenaBoston University's Undergraduate Research Opportunity Program, George Sherman Union, 775 Commonwealth Av, 5th floor, Boston, MA, 02215, USA.
Jacob A BeierleT32 Biomolecular Pharmacology PhD Program, Boston University Chobanian & Avedisian School of Medicine, USA; Boston University's Transformative Training Program in Addiction Science, Boston University Chobanian & Avedisian School of Medicine, 72 E. Concord St., L-317, Boston, MA, 02118, USA; Laboratory of Addiction Genetics, Department of Pharmacology, Physiology & Biophysics, Boston University Chobanian & Avedisian School of Medicine, 72 E. Concord St., L-606, Boston, MA, 02118, USA; Department of Pharmaceutical Sciences, Center for Drug Discovery, Northeastern University, 360 Huntington Av, 140 The Fenway Building, X138, Boston, MA, 02115, USA.
Michelle A RoosLaboratory of Addiction Genetics, Department of Pharmacology, Physiology & Biophysics, Boston University Chobanian & Avedisian School of Medicine, 72 E. Concord St., L-606, Boston, MA, 02118, USA; Department of Pharmaceutical Sciences, Center for Drug Discovery, Northeastern University, 360 Huntington Av, 140 The Fenway Building, X138, Boston, MA, 02115, USA.
Huiping ZhangDepartment of Psychiatry, Boston University Chobanian and Avedisian School of Medicine, 72 E. Concord St., Boston, MA, 02118, USA.
Elisha M WachmanDepartment of Pediatrics, Boston University Chobanian and Avedisian School of Medicine and Boston Medical Center, 1 Boston Medical Center Pl, Boston, MA, 02118, USA.
Camron D BryantLaboratory of Addiction Genetics, Department of Pharmacology, Physiology & Biophysics, Boston University Chobanian & Avedisian School of Medicine, 72 E. Concord St., L-606, Boston, MA, 02118, USA; Department of Pharmaceutical Sciences, Center for Drug Discovery, Northeastern University, 360 Huntington Av, 140 The Fenway Building, X138, Boston, MA, 02115, USA. Electronic address: c.bryant@northeastern.edu.
Boston University · US

Funding

TRAINING IN BIOMOLECULAR PHARMACOLOGYT32GM008541 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FARB, DAVID H · 1997 to 2022
$5.2M
A Reduced Complexity Cross in BALB/c substrains to identify the genetic basis of oxycodone dependence phenotypesU01DA050243 · NIDA · NORTHEASTERN UNIVERSITY · PI BRYANT, CAMRON D, ZACHARIOU, VENETIA · 2020 to 2023
$3.3M
Systems genetics of premorbid and cocaine use traits in a rat reduced complexity crossU01DA055299 · NIDA · NORTHEASTERN UNIVERSITY · PI BRYANT, CAMRON D, KANTAK, KATHLEEN M. · 2022 to 2025
$2.8M
NIDA NIH HHS U01 DA050243NIDA NIH HHS U01 DA055299NIGMS NIH HHS T32 GM008541
6 · The paper itself

Abstract

Prenatal opioid exposure is a major health concern in the United States, with the incidence of neonatal opioid withdrawal syndrome (NOWS) escalating in recent years. NOWS occurs upon cessation of in utero opioid exposure and is characterized by increased irritability, disrupted sleep patterns, high-pitched crying, and dysregulated feeding. The main pharmacological strategy for alleviating symptoms is treatment with replacement opioids. The neural mechanisms mediating NOWS and the long-term neurobehavioral effects are poorly understood. We used a third trimester-approximate model in which neonatal outbred pups (Carworth Farms White; CFW) were administered once-daily morphine (15 mg/kg, s.c.) from postnatal day (P) day 1 through P14 and were then assessed for behavioral and transcriptomic adaptations within the nucleus accumbens (NAc) on P15. We also investigated the long-term effects of perinatal morphine exposure on adult learning and reward sensitivity. We observed significant weight deficits, spontaneous thermal hyperalgesia, and altered ultrasonic vocalization (USV) profiles following repeated morphine and during spontaneous withdrawal. Transcriptome analysis of NAc from opioid-withdrawn P15 neonates via bulk mRNA sequencing identified an enrichment profile consistent with downregulation of myelin-associated transcripts. Despite the neonatal behavioral and molecular effects, there were no significant long-term effects of perinatal morphine exposure on adult spatial memory function in the Barnes Maze, emotional learning in fear conditioning, or in baseline or methamphetamine-potentiated reward sensitivity as measured via intracranial self-stimulation. Thus, the once daily third trimester-approximate exposure regimen, while inducing NOWS model traits and significant transcriptomic effects in neonates, had no significant long-term effects on adult behaviors.

Indexed as

Neonatal Abstinence SyndromeOpioid-Related DisordersSubstance Withdrawal SyndromeAnalgesics, OpioidAnimalsFemaleGene ExpressionMiceMorphineMyelin SheathNarcoticsNucleus AccumbensPregnancyAnalgesics, OpioidMorphineNarcoticsICSSNeonatal abstinence syndromeNeonatal opioid withdrawal syndromeOpiateOpioid use disorderRNA-seqSwiss webster

Identifiers

PMID37774943
PMCPMC10598517
OpenAlexW4387095423

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.